Volume 31, Issue 6 , Pages 1213-1218, June 2005
Hyaluronic acid combined with mannitol to improve protection against free-radical endothelial damage: Experimental Model
Purpose
To evaluate the protective properties of combined sodium hyaluronate 2% and mannitol 0.5% (Visiol) on the corneal endothelium in the presence of oxidative stress induced by hydrogen peroxide (H2O2).
Setting
Instituto Oftalmológico de Alicante, Universidad Miguel Hernández, Alicante, Spain.
Methods
This was an exploratory randomized controlled parallel-group, masked-assessor study of 3 sodium hyaluronate-based ophthalmic viscosurgical devices (OVDs): Visiol, Healon (sodium hyaluronate 1%), and Viscoat (sodium hyaluronate 3%–chondroitin sodium 4%). The OVDs were tested for protective effects on the endothelium following oxidative stress induced by H2O2 at increased concentrations: control (lactated Ringer's solution), 1 mM, 10 mM, and 100 mM. Groups without OVD were used as controls at the same concentrations of peroxide. Each animal received the same treatment in both eyes (10 eyes per group). Endothelial cell lesion was assessed using the Janus green photometry absorbance technique.
Results
At 10 mM peroxide concentration, the value of endothelial cell lesion was significantly lower in the Visiol (16.8%, P
=
.0056), Healon (22.2%, P
=
.0302), and Viscoat (21.6%, P
=
.0336) groups than in the control group (29.4%, no OVD). There was a trend in favor of Visiol to more efficiently reduce cell lesions of the endothelium, than Healon (P
=
.055) and Viscoat (P
=
.1013). Values of endothelial cell lesion at peroxide concentrations of 1 mM and 100 mM showed the same trends than those observed at 10 mM.
Conclusions
All of the OVDs tested efficiently reduced endothelial lesions against free radicals compared with the control group in which no OVD was used. The following sequence for the efficacy of endothelial cell protection was established: Visiol
>
Viscoat
>
Healon
>
no OVD.
To access this article, please choose from the options below
Vincent Baeyens, PhD, is an employee of TRB Chemedica SA. No other author has a financial or proprietary interest in any material or method mentioned.Presented in part at the annual meeting of the Association for Research and Vision in Ophthalmology, Fort Lauderdale, Florida, USA, May 2003, and the XXIst Congress of the European Society of Cataract & Refractive Surgeons, Munich, Germany, September 2003.Dr. J.A. Pérez de Gracia and the Servicio de Experimentación Animal, Universidad Miguel Hernández gave support and assistance.
PII: S0886-3350(05)00155-0
doi:10.1016/j.jcrs.2004.11.055
© 2005 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.
Volume 31, Issue 6 , Pages 1213-1218, June 2005
